Tags

Type your tag names separated by a space and hit enter

Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery.
Int J Nanomedicine. 2013; 8:3489-505.IJ

Abstract

The aim of this study was to design and develop respirable antibiotics moxifloxacin (MOXI) hydrochloride and ofloxacin (OFLX) microparticles and nanoparticles, and multifunctional antibiotics particles with or without lung surfactant 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) for targeted dry powder inhalation delivery as a pulmonary nanomedicine. Particles were rationally designed and produced by advanced spray-drying particle engineering from an organic solution in closed mode (no water) from dilute solution. Scanning electron microscopy indicated that these particles had both optimal particle morphology and surface morphology, and the particle size distributions were suitable for pulmonary delivery. Comprehensive and systematic physicochemical characterization and in vitro aerosol dispersion performance revealed significant differences between these two fluoroquinolone antibiotics following spray drying as drug aerosols and as cospray-dried antibiotic drug: DPPC aerosols. Fourier transform infrared spectroscopy and confocal Raman microspectroscopy were employed to probe composition and interactions in the solid state. Spray-dried MOXI was rendered noncrystalline (amorphous) following organic solution advanced spray drying. This was in contrast to spray-dried OFLX, which retained partial crystallinity, as did OFLX:DPPC powders at certain compositions. Aerosol dispersion performance was conducted using inertial impaction with a dry powder inhaler device approved for human use. The present study demonstrates that the use of DPPC offers improved aerosol delivery of MOXI as cospray-dried microparticulate/nanoparticulate powders, whereas residual partial crystallinity influenced aerosol dispersion of OFLX and most of the compositions of OFLX:DPPC inhalation powders.

Authors+Show Affiliations

University of Kentucky College of Pharmacy, Department of Pharmaceutical Sciences - Drug Development Division, Lexington, KY, USA ; University of Washington-Seattle, College of Pharmacy, Department of Pharmaceutics, Seattle, WA, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24092972

Citation

Duan, Jinghua, et al. "Design, Characterization, and Aerosolization of Organic Solution Advanced Spray-dried Moxifloxacin and Ofloxacin Dipalmitoylphosphatidylcholine (DPPC) Microparticulate/nanoparticulate Powders for Pulmonary Inhalation Aerosol Delivery." International Journal of Nanomedicine, vol. 8, 2013, pp. 3489-505.
Duan J, Vogt FG, Li X, et al. Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. Int J Nanomedicine. 2013;8:3489-505.
Duan, J., Vogt, F. G., Li, X., Hayes, D., & Mansour, H. M. (2013). Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. International Journal of Nanomedicine, 8, 3489-505. https://doi.org/10.2147/IJN.S48631
Duan J, et al. Design, Characterization, and Aerosolization of Organic Solution Advanced Spray-dried Moxifloxacin and Ofloxacin Dipalmitoylphosphatidylcholine (DPPC) Microparticulate/nanoparticulate Powders for Pulmonary Inhalation Aerosol Delivery. Int J Nanomedicine. 2013;8:3489-505. PubMed PMID: 24092972.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. AU - Duan,Jinghua, AU - Vogt,Frederick G, AU - Li,Xiaojian, AU - Hayes,Don,Jr AU - Mansour,Heidi M, Y1 - 2013/09/17/ PY - 2013/10/5/entrez PY - 2013/10/5/pubmed PY - 2014/4/5/medline KW - aerosol KW - fluoroquinolone antibiotic drug delivery KW - lung infection KW - lung surfactant KW - respiratory KW - solid-state particle engineering design SP - 3489 EP - 505 JF - International journal of nanomedicine JO - Int J Nanomedicine VL - 8 N2 - The aim of this study was to design and develop respirable antibiotics moxifloxacin (MOXI) hydrochloride and ofloxacin (OFLX) microparticles and nanoparticles, and multifunctional antibiotics particles with or without lung surfactant 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) for targeted dry powder inhalation delivery as a pulmonary nanomedicine. Particles were rationally designed and produced by advanced spray-drying particle engineering from an organic solution in closed mode (no water) from dilute solution. Scanning electron microscopy indicated that these particles had both optimal particle morphology and surface morphology, and the particle size distributions were suitable for pulmonary delivery. Comprehensive and systematic physicochemical characterization and in vitro aerosol dispersion performance revealed significant differences between these two fluoroquinolone antibiotics following spray drying as drug aerosols and as cospray-dried antibiotic drug: DPPC aerosols. Fourier transform infrared spectroscopy and confocal Raman microspectroscopy were employed to probe composition and interactions in the solid state. Spray-dried MOXI was rendered noncrystalline (amorphous) following organic solution advanced spray drying. This was in contrast to spray-dried OFLX, which retained partial crystallinity, as did OFLX:DPPC powders at certain compositions. Aerosol dispersion performance was conducted using inertial impaction with a dry powder inhaler device approved for human use. The present study demonstrates that the use of DPPC offers improved aerosol delivery of MOXI as cospray-dried microparticulate/nanoparticulate powders, whereas residual partial crystallinity influenced aerosol dispersion of OFLX and most of the compositions of OFLX:DPPC inhalation powders. SN - 1178-2013 UR - https://www.unboundmedicine.com/medline/citation/24092972/Design_characterization_and_aerosolization_of_organic_solution_advanced_spray_dried_moxifloxacin_and_ofloxacin_dipalmitoylphosphatidylcholine__DPPC__microparticulate/nanoparticulate_powders_for_pulmonary_inhalation_aerosol_delivery_ L2 - https://dx.doi.org/10.2147/IJN.S48631 DB - PRIME DP - Unbound Medicine ER -